Clinical trial
Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome: Observational Study
NCT04732650 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real World Difference After Changing Medication From Nonselective to Selective Endothelin Receptor Antagonist in Stable Eisenmenger Syndrome: Observational Study
- Lead sponsor
- Samsung Medical Center
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- February 4, 2021
- Completion date
- December 31, 2024
- Enrollment
- 40 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.